Techno Science
VC Fund
Kashiwa, Japan
Techno Science is a VC fund in Kashiwa focused on Therapeutics and Medical. Techno Science primarily engages in the technology development business.
- Total investments:
- 4
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Techno Science invests in
Stages Techno Science invests in
Countries Techno Science invests in
Investment Focus
Industry
- Therapeutics 2 (50%)
- Medical 1 (25%)
- Health Care 1 (25%)
- Biotechnology 1 (25%)
- Manufacturing 1 (25%)
Stage
- Series A 1 (25%)
- Series B 1 (25%)
- Series D 1 (25%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Periotherapia is a Drug discovery business with triple negative breast cancer as the first indication. Periotherapia aims to selectively inhibit only ASV that is involved in pathogenesis without inhibiting physiological ASV in chronic diseases such as cancer, heart failure, arteriosclerosis, renal failure, and diabetic retinopathy. is. | $3.6M / Series D / May 26, 2026 | ||
| Celaid Therapeutics develops technologies and products based on hematopoietic stem cell (HSC) expansion and gene-augmented therapies. The company operates a platform that enables in-vitro propagation of human HSCs without relying on animal-derived components, facilitating scalability, consistency, and cost control. It applies this platform acrossworkflows, including donor/patient cell collection, HSC expansion, cell processing, and gene editing to deliver cell therapy products. Celaid advances pipelines in areas such as blood cancers, genetic disorders, and rare hematologic diseases. Through partnerships and internal research, it seeks to support both reagent/media supply and therapeutic development around HSC-based regenerative medicine. | $3.6M / Series B / Oct 07, 2025 | ||
| Celaid Therapeutics develops technologies and products based on hematopoietic stem cell (HSC) expansion and gene-augmented therapies. The company operates a platform that enables in-vitro propagation of human HSCs without relying on animal-derived components, facilitating scalability, consistency, and cost control. It applies this platform acrossworkflows, including donor/patient cell collection, HSC expansion, cell processing, and gene editing to deliver cell therapy products. Celaid advances pipelines in areas such as blood cancers, genetic disorders, and rare hematologic diseases. Through partnerships and internal research, it seeks to support both reagent/media supply and therapeutic development around HSC-based regenerative medicine. | $3M / Series A / May 08, 2024 | ||
| Celaid Therapeutics develops technologies and products based on hematopoietic stem cell (HSC) expansion and gene-augmented therapies. The company operates a platform that enables in-vitro propagation of human HSCs without relying on animal-derived components, facilitating scalability, consistency, and cost control. It applies this platform acrossworkflows, including donor/patient cell collection, HSC expansion, cell processing, and gene editing to deliver cell therapy products. Celaid advances pipelines in areas such as blood cancers, genetic disorders, and rare hematologic diseases. Through partnerships and internal research, it seeks to support both reagent/media supply and therapeutic development around HSC-based regenerative medicine. | $3.4M / Series A / Oct 25, 2022 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Techno Science invest in?
Techno Science invests primarily in Therapeutics, Medical and Health Care startups, most often at Series A and Series B stage. Most of the 4 investments tracked by Shizune back companies in Japan. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Techno Science last invest?
The most recent investment recorded for Techno Science closed in May 2026. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
